Study type

Study topic

Disease /health condition

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Other

If ‘other’, further details on the scope of the study

Impact and risk

Data collection methods

Secondary data collection
Non-interventional study

Non-interventional study design

Cohort
Other

Non-interventional study design, other

Population based, retrospective cohort study
Study drug and medical condition

Medical condition to be studied

Immunodeficiency common variable
Population studied

Short description of the study population

Immunosuppressed subjects ≥ 18 years in the Valencian Community, between 2009 and 2014.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Immunocompromised

Estimated number of subjects

4382590
Study design details

Main study objective

To estimate the incidence of HZ in IS subjects 18 years and older in Valencia Region, from 2009 to 2014, both globally and stratified by age groups, sex and immunodeficiency type (HIV, malignancies, organ transplantation, immunodeficiency disorders and autoimmune diseases)

Outcomes

An incident case of HZ will be considered the first appearance of a HZ-related ICD-9-CM code (053.xx), in either SIA or CMBD (in any position). Any outpatient medical contact or visit, or hospital admission related to HZ will be considered as a medical encounter. Recurrence of HZ will be examined in all HZ incident cases. - Health care resources consumption due to HZ:Outpatient visit.Hospitalizations.Length of hospitalization.Medication.Periods off work.- Health care resources consumption due to IS:Outpatient visits.Hospitalizations.Length of hospitalization.- HZ complications - Post-herpetic Neuralgia- Comorbidities

Data analysis plan

We might expect approx. 4 million subjects to fulfil the inclusion criteria. Internal data from a previous study from our team, using the same health databases from Valencia Region and the same ICD-9 codes showed a prevalence of IS of 11.8% in subjects ≥ 50 years old. These data correlate with a published work with a large study population of 51 million subjects and a prevalence of IS of 11.9% for subjects ≥ 50 years old 9. According to this and the published data, the observed prevalence of IS for subjects aged 18 years and older was approx. 7% so, we will expect around 280.000 IS subjects in the present study.